Our Mission

To characterize your proprietary compounds with the integrative approach to cardiac safety & function.  We are here to help you with experimental design, data interpretation, and guidance for the next step in the drug discovery process.

  • Published Articles
  • Cell-Based Assays
  • Isolated Tissue
  • In Vivo Models
David Fedida, Ph.D., B.M., B.Ch.

David Fedida, Ph.D., B.M., B.Ch.


Dr. David Fedida is Professor of Anesthesiology, Pharmacology and Therapeutics, at the University of British Columbia, where, for the past ten years he has been actively involved in the discovery and mechanisms of action of Vernakalant as a new treatment for the acute conversion of atrial fibrillation to sinus rhythm.

Dr. Fedida has a major interest in ion currents underlying human cardiac repolarization, and how they affect cardiac rhythmicity. He was the first to identify the human heart potassium current IKur with the KCNA5 gene product, a current which has subsequently become an important atria-selective target for the treatment of atrial fibrillation, and he leads a research group at the University of British Columbia investigating human heart potassium channels and the remodeling of cardiac ion channels in diseases like Long QT syndrome.

Dr. Fedida obtained his B.Sc. and Ph.D from the University of Leeds and his MD from Oxford in the UK, and after postgraduate medical training and positions at universities in Canada and the US, since 1998 he has been at the University of British Columbia in Canada, where he was until recently Associate Head of Anesthesiology, Pharmacology and Therapeutics and Associate Dean Research in the Faculty of Medicine.

Read Dr. Fedida’s Publications

Marc Pourrier, Ph.D.

Marc Pourrier, Ph.D.

Vice President, Operations

Dr. Pourrier has 15 years of experience in the field of electrophysiology and 7 years in drug discovery. After he obtained an under graduated diploma in Biochemistry in Paris, France, Marc moved to Montreal where he completed his Bachelor of Science at the University of Montreal in Biochemistry and his PhD in Pharmacology under the supervision of Dr. Stanley Nattel.

During his PhD, Marc studied the electrophysiological and molecular properties of voltage gated potassium channels. After graduating in 2004, Marc completed a 1 year post-doctoral fellowship at the Montreal Heart Institute, funded by Wyeth US. In April 2005, Marc joined Cardiome Pharma Corp where he was responsible for carrying out studies on the mechanism of action of the atrial antiarrhythmic drug vernakalant. In 2007, Marc became the group leader, electrophysiology.

In this role, Marc joined the Vernakalant Development Team, in which he played a key role not only in the development, but also in regulatory filling (European approval in 2010) and out licensing to Merck of vernakalant. In 2011-2012, Marc acted as a Discovery Project Lead where he was responsible for the day-to-day operations and for coordinating project activities of multidisciplinary teams.

Read Dr. Pourrier’s Publications

Partners of IonsGate

Ncardia provides cardiomyocytes and other in vitro differentiated cells derived from embryonic and induced pluripotent stem cells of murine and human origin. Also provided are in-house services in the field of toxicity testing,notably embryotoxicity, cardiotoxicity and general cytotoxicity.

Gateway Pharmacology Laboratories is a preclinical CRO that conducts cardiovascular disease and safety pharmacology studies in relevant in vivo models.  Our services include BP, HR and ECG studies utilizing radio-telemetry as well as chronic infusion studies.

IonsGate Preclinical Services

IonsGate Preclinical Services Inc., 2350 Health Sciences Mall, Vancouver, British Columbia, Canada, V6T 1Z3

Contact Us

Share This